Evidence map›Paper›PMID 42382876›Full record

ArticleCureus2026

Brain Arteriovenous Malformations Treated With Linear Accelerator-Based Stereotactic Radiosurgery: A Single-Institution Retrospective Experience From Latin America.

Valentina Rangel-Sarmiento, Beatriz Soto-Cala, Juanita Cure, Maria Caicedo-Martinez, German Borda, Carlos A Lindado, Esperanza Castro-Lombana, Juan C Puentes, Oscar Zorro, Edwin O Pulido-Ramirez and 1 more

Abstract read
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Valentina Rangel-SarmientoOncology Research Group, Faculty of Medicine, Pontificia Universidad Javeriana, Bogota, COL.
Beatriz Soto-CalaOncology Research Group, Faculty of Medicine, Pontificia Universidad Javeriana, Bogota, COL.
Juanita CureOncology Research Group, Faculty of Medicine, Pontificia Universidad Javeriana, Bogota, COL.
Maria Caicedo-MartinezJaveriana Oncology Center, Hospital Universitario San Ignacio, Bogota, COL.
German BordaOncology Research Group, Faculty of Medicine, Pontificia Universidad Javeriana, Bogota, COL.
Carlos A LindadoNeurosurgery Department, Hospital Universitario San Ignacio, Bogota, COL.
Esperanza Castro-LombanaJaveriana Oncology Center, Hospital Universitario San Ignacio, Bogota, COL.
Juan C PuentesNeurosurgery Department, Hospital Universitario San Ignacio, Bogota, COL.
Oscar ZorroNeurosurgery Department, Hospital Universitario San Ignacio, Bogota, COL.
Edwin O Pulido-RamirezInstitute for Research, Science, and Education, GIGA Research Group, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogota, COL.
Alejandro Gonzalez-MottaJaveriana Oncology Center, Hospital Universitario San Ignacio, Bogota, COL.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Stereotactic radiosurgery (SRS) is an established treatment option for selected patients with brain arteriovenous malformations (bAVMs), particularly for lesions not amenable to microsurgical resection or located in surgically high-risk areas. SRS can be delivered through different platforms, including Gamma Knife, CyberKnife, and linear accelerator (LINAC)-based systems. This retrospective single-institution study evaluated outcomes of patients with bAVMs treated with LINAC-based SRS at a quaternary care center in Bogotá, Colombia. Materials and methods We conducted a retrospective observational study of patients with bAVMs treated with LINAC-based SRS guided by triple-fusion imaging between 2011 and 2017. Clinical, treatment, and imaging data were collected from medical records. Telephone interviews were used only to supplement clinical follow-up and were not used to determine radiological obliteration. The primary outcome was radiological obliteration during the available follow-up period, assessed by follow-up imaging. Actuarial obliteration rates were estimated using Kaplan-Meier analysis and interpreted as exploratory because of limited follow-up and censoring. Univariable Cox proportional hazards analyses were performed as exploratory analyses to evaluate factors associated with obliteration. Results Eighty-two patients were included. At presentation, 36 patients (44.0%) had ruptured bAVMs, 61 (74.4%) had lesions in eloquent areas, and most had Spetzler-Martin grade III malformations. Prior embolization was performed in 47 patients (57.3%). Complete radiological obliteration was documented in 27 patients (33.0%) during available follow-up. The median follow-up was 16.3 months, and 46 patients (56.1%) were lost to follow-up before completing three years of institutional follow-up. Actuarial obliteration estimates at later time points should therefore be interpreted cautiously. In exploratory univariable Cox analysis, radiosurgery dose >20 Gy was associated with a shorter time to obliteration. Conclusions This single-institution retrospective study describes radiological and clinical outcomes after LINAC-based SRS for bAVMs in a Latin American quaternary care center. The findings suggest that LINAC-based SRS is a feasible treatment approach when appropriate technology, planning expertise, and quality assurance are available. However, the short median follow-up, substantial loss to follow-up, and lack of a comparator group limit conclusions regarding effectiveness. Future prospective studies with standardized long-term imaging follow-up are needed.

Indexed as

brain arteriovenous malformationslatin americalinear acceleratorradiosurgery outcomesstereotactic radiosurgeryvascular malformations

Identifiers

PMID42382876
PMCPMC13317816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.